RYTM (RYTM) EVP Yann Mazabraud receives 23,350 restricted stock units

Rhea-AI Filing Summary

Mazabraud Yann reported acquisition or exercise transactions in this Form 4 filing.

Pharmaceuticals, Inc. executive Yann Mazabraud, EVP and Head of International, reported receiving a grant of 23,350 restricted stock units on February 11, 2026. This was an award of derivative securities at a reported price of $0 per unit, held as direct ownership.

The restricted stock units give a contingent right to receive one share of common stock for each unit. They vest in four equal installments of 25% of the total grant on March 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030, and have no expiration date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazabraud Yann

(Last) (First) (Middle)

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of International

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/11/2026		A		23,350		(2)	(2)	Common Stock	23,350	$0	23,350	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of March 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Yann Mazabraud	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RYTM executive Yann Mazabraud report?

Yann Mazabraud reported receiving 23,350 restricted stock units. The award was granted on February 11, 2026 as a derivative security, at a reported price of $0 per unit, and is held as directly owned equity-linked compensation.

How many restricted stock units did RYTM grant to Yann Mazabraud?

RYTM granted 23,350 restricted stock units to Yann Mazabraud. Each restricted stock unit represents a contingent right to receive one share of the company’s common stock, subject to the vesting schedule described in the filing’s footnotes.

What is the vesting schedule for Yann Mazabraud’s RYTM restricted stock units?

The units vest in four equal annual installments of 25% each. Vesting occurs on March 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030, according to the schedule disclosed for the 23,350 restricted stock units.

Do the restricted stock units granted to the RYTM executive have an expiration date?

The restricted stock units have no expiration date. They remain outstanding subject to their vesting schedule, which requires service through four annual vesting dates before the underlying common shares are delivered to the executive.

What role does the reporting person hold at RYTM?

The reporting person, Yann Mazabraud, serves as EVP, Head of International. This officer role is explicitly listed in the filing, indicating the transaction relates to equity compensation for a senior executive of Pharmaceuticals, Inc. (ticker RYTM).

Is Yann Mazabraud’s RYTM equity award a market purchase or a compensation grant?

The filing characterizes it as a grant or award acquisition. Transaction code “A” and the description “grant, award, or other acquisition” indicate this is equity compensation, not an open-market stock purchase or sale by the executive.